Fig. 1From: Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumabMean changes in BCVA after intravitreal ranibizumab injection with respect to the baseline and at each follow-up in the two groups. Bars indicate 95% confidence intervals. NLR neutrophil-to-lymphocyte ratio; BCVA best-corrected visual acuityBack to article page